drugset / Trial / NCT06353906
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis
Timeline
- Start
- 2024-08-13
- Primary completion
- 2026-10-14
- Completion
- 2028-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 750 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |